CompletedNCT00830739
A Multi-Modal Investigation of the Smoking Cessation Medication Varenicline: Dopaminergic Modulation of Reward Processing and Cognitive Control
Observational studyAges 18–55United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- BaltimoreSee all locations and recruitment
Study information
Study start dateNovember 25, 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 61
- Sponsor
- National Institute on Drug Abuse (NIDA)
- Sponsor type
- Research institute
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Study phase
- Not clearly listed
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00830739
- Official title
Show the full official title
A Multi-Modal Investigation of the Smoking Cessation Medication Varenicline: Dopaminergic Modulation of Reward Processing and Cognitive Control
Get this study by email
Recruitment & locations
CompletedBaltimore
Questions about this study
Who is behind this study?
The study sponsor is National Institute on Drug Abuse (NIDA), a research institute.
Who was this study for?
Listed age limits: 18 years to 55 years.
Want to explore more studies?
Explore studiesRelated studies
'Keepin' It REAL in Mexico: An Adaptation and Multisite RCT Implementation of a Substance Abuse Prevention Curriculum for Adolescents in Three Mexico Cities.
A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings ("CDE-EHR-PC" Study), Phase 1